General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.
about
Exploring patients' treatment journeys following randomisation in mental health trials to improve future trial conduct: a synthesis of multiple qualitative data setsEfficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.Extended release quetiapine fumarate as adjunct to antidepressant therapy in patients with major depressive disorder: pooled analyses of data in patients with anxious depression versus low levels of anxiety at baseline.Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase InhibitorsImpact of treatments for depression on comorbid anxiety, attentional, and behavioral symptoms in adolescents with selective serotonin reuptake inhibitor-resistant depression.Neurocognitive Predictors of Response in Treatment Resistant Depression to Subcallosal Cingulate Gyrus Deep Brain Stimulation.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.Burning issues in the meta-analysis of pharmaceutical trials for depression.Report of the WPA section of pharmacopsychiatry on the relationship of antiepileptic drugs with suicidality in epilepsy.Antidepressant monotherapy compared with combinations of antidepressants in the treatment of resistant depressive patients: a randomized, open-label study.Effects of anti-depressant treatments on FADD and p-FADD protein in rat brain cortex: enhanced anti-apoptotic p-FADD/FADD ratio after chronic desipramine and fluoxetine administration.Efficacy and tolerability of trazodone retard monotherapy: results of the Serbian non-interventional study.On the application of light therapy in German-speaking countries.Why are new antidepressants failing to make the grade for approval?
P2860
Q33805242-C386190C-D849-4A44-A7E1-21846D06A96CQ34629315-7433E57B-91E1-40DD-A254-64A58E6198DAQ35088837-BA63E55D-B181-4C3A-8109-956E149210DEQ36634033-DEDF0844-5278-4205-A087-0B4A14E0FC6EQ37130105-4F4B7CBF-92F3-497D-B0F6-2D8B2B56564BQ37662570-EC5ED91A-B5C7-4FE5-BE7D-847A52919143Q38123516-70B70E11-50FB-4833-BD8F-C0242E5D365DQ38138536-4AF2AB13-3CF6-4E86-9585-7DFED2FACFA9Q38303164-FA8C08E6-74C3-46F2-87B7-BFC6DE242058Q43716603-E841CA52-15DF-4E6B-83C0-97F362EEE759Q47423746-3ADD65EF-B8A2-42A4-BD56-C181320C4289Q47996390-9ABF480A-1026-4772-8FA1-FC2433470804Q48763877-C06FAADD-0939-4E02-BFB4-40EAA397E044Q53398572-86C30008-241C-485F-A9EC-D39E0642766A
P2860
General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
General and comparative effica ...... section of pharmacopsychiatry.
@en
General and comparative effica ...... section of pharmacopsychiatry.
@nl
type
label
General and comparative effica ...... section of pharmacopsychiatry.
@en
General and comparative effica ...... section of pharmacopsychiatry.
@nl
prefLabel
General and comparative effica ...... section of pharmacopsychiatry.
@en
General and comparative effica ...... section of pharmacopsychiatry.
@nl
P2093
P2860
P50
P1476
General and comparative effica ...... section of pharmacopsychiatry.
@en
P2093
Brian E Leonard
David S Baldwin
Guy M Goodwin
Kostas N Fountoulakis
Marcio Versiani
Michael Bauer
Pierre Blier
Section of Pharmacopsychiatry, World Psychiatric Association
Thomas C Baghai
P2860
P2888
P304
P356
10.1007/S00406-011-0259-6
P478
261 Suppl 3
P577
2011-11-01T00:00:00Z